ENVB
Income statement / Annual
Last year (2024), Enveric Biosciences, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Enveric Biosciences, Inc.'s net income was -$9.57 M.
See Enveric Biosciences, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$39.91 M |
$43.00 M |
$48.59 M |
$36.15 M |
$15.98 M |
| Cost of Revenue |
$337.49 K
|
$408.03 K
|
$435.20 K
|
$681.61 K
|
$120.87 K
|
$31.76 M
|
$34.01 M
|
$38.36 M
|
$29.61 M
|
$10.23 M
|
| Gross Profit |
-$337.49 K
|
-$408.03 K
|
-$435.20 K
|
-$681.61 K
|
-$120.87 K
|
$8.15 M
|
$8.98 M
|
$10.24 M
|
$6.54 M
|
$5.75 M
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0.2
|
0.21
|
0.21
|
0.18
|
0.36
|
| Research and Development Expenses |
$2.84 M
|
$7.25 M
|
$8.03 M
|
$4.79 M
|
$174.08 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$0.00
|
$8.85 M
|
$0.00
|
$0.00
|
$0.00
|
$2.30 M
|
$0.00
|
$0.00
|
$8.55 M
|
$5.69 M
|
| Selling & Marketing Expenses |
$0.00
|
-$64.05 K
|
$0.00
|
$0.00
|
$0.00
|
$9.91 M
|
$0.00
|
$0.00
|
$417.25 K
|
$119.85 K
|
| Selling, General & Administrative Expenses |
$6.45 M
|
$8.79 M
|
$11.50 M
|
$20.47 M
|
$5.32 M
|
$12.21 M
|
$10.79 M
|
$18.51 M
|
$8.97 M
|
$5.81 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$2.27 M
|
$88.16 K
|
$1.08 M
|
-$394.21 K
|
$157.94 K
|
| Operating Expenses |
$9.29 M
|
$16.04 M
|
$19.53 M
|
$25.26 M
|
$5.50 M
|
$14.48 M
|
$13.70 M
|
$21.73 M
|
$10.33 M
|
$5.97 M
|
| Cost And Expenses |
$9.63 M
|
$16.45 M
|
$19.96 M
|
$25.94 M
|
$5.62 M
|
$46.24 M
|
$47.71 M
|
$60.08 M
|
$39.94 M
|
$16.19 M
|
| Interest Income |
$219.00
|
$0.00
|
$5.25
|
$10.32
|
$445.25
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$89.92 K
|
| Interest Expense |
$0.00
|
$3.71 K
|
$5.25 K
|
$10.32 K
|
$445.25 K
|
$691.14 K
|
$729.90 K
|
$575.04 K
|
$751.07 K
|
$238.47 K
|
| Depreciation & Amortization |
$337.49 K
|
$408.03 K
|
$435.20 K
|
$681.61 K
|
$120.87 K
|
$2.27 M
|
$2.90 M
|
$3.22 M
|
$1.36 M
|
$157.94 K
|
| EBITDA |
-$9.23 M |
-$16.85 M |
-$19.52 M |
-$55.74 M |
-$6.30 M |
-$2.26 M |
-$6.92 M |
-$7.67 M |
-$4.41 M |
-$537.78 K |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
-0.06
|
-0.16
|
-0.16
|
-0.12
|
-0.03
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
-0.16
|
-0.17
|
-0.25
|
-0.15
|
-0.12
|
| Total Other Income/Expenses Net |
$66.21 K
|
-$814.38 K
|
$4.05 K
|
-$30.49 M
|
-$1.25 M
|
$1.11 M
|
-$10.55 M
|
-$11.47 M
|
-$2.73 M
|
-$1.23 M
|
| Income Before Tax |
-$9.57 M
|
-$17.26 M
|
-$19.96 M
|
-$56.43 M
|
-$6.86 M
|
-$5.22 M
|
-$10.55 M
|
-$11.47 M
|
-$6.53 M
|
-$2.02 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
-0.13
|
-0.25
|
-0.24
|
-0.18
|
-0.13
|
| Income Tax Expense |
$8.93 K
|
$28.91 K
|
-$1.49 M
|
-$7.45 M
|
$0.00
|
$388.66 K
|
$6.35 M
|
-$2.39 M
|
-$3.75 M
|
-$128.46 K
|
| Net Income |
-$9.57 M
|
-$17.29 K
|
-$18.50 M
|
-$48.98 M
|
-$6.86 M
|
-$5.60 M
|
-$16.90 M
|
-$9.07 M
|
-$2.78 M
|
-$1.89 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
-0.14
|
-0.39
|
-0.19
|
-0.08
|
-0.12
|
| EPS |
-228.48 |
-97.08 |
-87.72 |
-1244.28 |
-666 |
-2543.88 |
-42616.68 |
-36347.76 |
-12770.04 |
-10272.72 |
| EPS Diluted |
-228.48 |
-97.08 |
-156 |
-1244.28 |
-666 |
-2543.88 |
-42616.68 |
-36347.76 |
-12770.04 |
-10220.28 |
| Weighted Average Shares Out |
$41.91 K
|
$210.63 K
|
$210.63 K
|
$39.36 K
|
$9.59 K
|
$2.20 K
|
$396.00
|
$250.00
|
$218.00
|
$198.00
|
| Weighted Average Shares Out Diluted |
$41.91 K
|
$179.92 K
|
$173.19 K
|
$39.36 K
|
$9.59 K
|
$2.20 K
|
$396.00
|
$250.00
|
$218.00
|
$185.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
